By Abujah Racheal
In an interview with the Nigeria News Agency (NAN) on Monday in Abuja, Shuaib said there were several COVID-19 vaccine candidates.
He said while some had been approved for emergency use by the World Health Organization (WHO), others were still in different stages of clinical trials for possible approval.
According to him, the COVID-19 vaccine candidates are of various categories according to their mechanism of action such as inactivated or weakened virus vaccines.
He explained that in the formulation of the COVID-19 vaccine, an inactivated or weakened virus is used so that it does not cause disease, but generates an immune response.
He also said that there are protein-based vaccines, which use harmless fragments of proteins or protein shells that mimic the COVID-19 virus to safely generate an immune response.
He added that the viral vector vaccines used a virus that had been genetically engineered so as not to cause disease but would produce coronavirus proteins to safely generate an immune response.
He added that the ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) vaccines used a cutting edge approach that used genetically engineered RNA or DNA to generate a protein that safely caused an immune response.
NAN reports that 1.09 million Nigerians received the first dose of the Astrazeneca vaccine.
Short Link: https://wp.me/pcj2iU-3yYc
- Chelsea whip Real Madrid to reach Champions League final
- Video press release: Weekly press briefing on the coronavirus epidemic
- Enugu State inaugurates board for universal health coverage
- Video Press Release: WHO Africa COVID-19 Online Briefing
- Singer Paul Okoye hits 1m subscribers on YouTube, receives gold plaque
- Coronavirus – Ethiopia: COVID-19 cases reported in Ethiopia (May 5, 2021)
- Coker resumes as NTDC boss
- WAPA reiterates commitment to vulnerable women in Lagos
- Coronavirus – Daily update on the status of COVID-19 statistics in Zambia (May 5, 2021)